LAUSR

Highlights • The nonspecific anticancer mechanism of action and the consistently favorable toxicity profile of TTFields represent a solid basis for their utilization as a cancer agnostic modality in various combination regimens.• The highly anticipated results of the ongoing phase II & III trials for thoracic and abdominal cavity cancers have the potential to be practice-changing, as was the case in the GBM studies.• Future directions in the study of TTFields will focus on biologically optimized treatment combinations to harness the maximum benefit of the modality based on improved understanding of intracellular and intercellular responses to TTFields, such as the induced autophagy and immunomodulation.